Incidence, Survival Rate and Prognostic Factors of Recurrent/ Refractory Epithelial
Keywords:
Epithelial ovarian cancer, prognosis, recurrenceAbstract
Objective: To assess the incidence, 5-year survival rate and identify the prognostic factors for survival in a cohort of patients with recurrent/ refractory epithelial ovarian cancer in Siriraj Hospital.
Methods: We performed a retrospective chart review of 140 patients with primary recurrent / refractory epithelial ovarian cancer who received their treatment at Siriraj Hospital between October 1998 and December 2006. Incidence, 5-year survival rate and potential prognostic factors for survival were identified. Statistical analysis was by SPSS for Windows version 11.5. Kaplan-Meier survival curves were computed and a multivariable proportional hazard model (Cox) was applied to assess the prognostic significance of the different covariates.
Results: The incidence of recurrent/refractory epithelial ovarian cancer when compared to total new cases of epithelial ovarian cancer during a 1-year period was 33.62%. The 5-year survival rate for the cohort was 47%, whereas the median overall survival was 4.91 years and the median survival post recurrence was 2.5 years. Of these patients, 64/140 (45.7%) have died of disease. Seventeen factors were evaluated for prognostic significance for survival, on multivariate analysis, only the tumor free interval (TFI) (P = 0.016) and CA 125 at the time of recurrence or refractory (P = 0.02) retained prognostic significance.
Conclusion: The incidence of recurrent/ refractory epithelial ovarian cancer when compared to total new cases of epithelial ovarian cancer is about one third. This cohort had a prolonged median overall survival and satisfied a 5-year survival rate. The significant prognostic factors for survival in a cohort of patients are the tumor free interval and CA 125 at time of recurrence or refractory.Â
Downloads
Published
How to Cite
Issue
Section
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.